2014
Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer.
Thomay A, Su S, Friedant A, Ruth K, Astsaturov I, Burtness B, Denlinger C, Dotan E, Hall M, Meyer J, Shah P, Cohen S, Scott W. Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer. Journal Of Clinical Oncology 2014, 32: 126-126. DOI: 10.1200/jco.2014.32.3_suppl.126.Peer-Reviewed Original ResearchEsophageal cancerOverall survivalGroup BLandmark analysisGroup ANeoadjuvant treatment regimenKaplan-Meier methodEsophageal cancer patientsProspective databaseR0 resectionDistant recurrencePatient demographicsSurgery patientsMeier methodMore recurrencesOperative complicationsPathologic responseTreatment regimenCancer patientsOperative procedurePatientsLarge seriesRecurrenceSurvival curvesPropensity score
2006
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma
Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs 2006, 24: 135-140. PMID: 16502351, DOI: 10.1007/s10637-006-5934-5.Peer-Reviewed Original ResearchConceptsPathologic complete response rateThrombo-embolic eventsParallel design studyModality therapyResponse rateAdvanced esophageal cancer patientsRandomized phase IIComplete response rateEvidence of diseaseProgression-free survivalEsophageal cancer patientsOverall response ratePhase IIAdjuvant paclitaxelConcurrent radiotherapyEligible patientsPreoperative treatmentMusculoskeletal toxicityOverall survivalResectable adenocarcinomaDisease relapsePreoperative stagingTreatment armsDisease improvementContinuous infusion